Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) May 01, 2014

The Durability of OnabotulinumtoxinA for the Treatment of Chronic Migraine: CLARITY Pilot Study (P7.186)

Andrew Blumenfeld, Andrew Inocelda, Cedric Cunanan, Chris Purdy, Laura Dalfonso, Raf Magar
First published April 9, 2014,
Andrew Blumenfeld
4Headache Center of Southern California Encinitas CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Inocelda
5The Neurology Center Oceanside CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cedric Cunanan
3Allergan Irvine CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Purdy
1AHRM Inc. Buffalo NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Dalfonso
2AHRM Inc. Raleigh NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raf Magar
2AHRM Inc. Raleigh NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
The Durability of OnabotulinumtoxinA for the Treatment of Chronic Migraine: CLARITY Pilot Study (P7.186)
Andrew Blumenfeld, Andrew Inocelda, Cedric Cunanan, Chris Purdy, Laura Dalfonso, Raf Magar
Neurology Apr 2014, 82 (10 Supplement) P7.186;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate the durability of benefit with onabotulinumtoxinA when given for 7-9 cycles on the number of headache (HA) days for patients with a confirmed diagnosis of chronic migraine. Background: Limited data exists on the durability of benefit beyond 5 cycles for the treatment of chronic migraine with onabotulinumtoxinA. Methods: Retrospective medical records review for patients with chronic migraine per ICHD - III beta criteria with 15 or more HA days per month. Patients must have had a baseline visit and at least 7 onabotulinumtoxinA injection cycles with an interval of 12 weeks (+/- 2 weeks) between injections. Dosing must have been within the range of 155-195U using the PREEMPT injection paradigm. Abstracted data included dose, headache days, MIDAS, HIT-6, and adverse events. Results: Thirty-three patients qualified with a minimum of 7 injections cycles. Of these patients, 17 had 8 cycles and 10 had 9 cycles. Mean HA days at baseline, cycles 7 and 9 were 19.08, 6.25 and 6.57, respectively. Mean HA free days at baseline, cycles 7 and 9 were 10.92, 23.75 and 23.43, respectively. Proportion of patients achieving >50% reduction in HA days at cycles 7 and 9 were 85% and 90%, respectively. Proportion of patients considered incapacitated based on MIDAS scores at baseline and cycle 7 were 53% and 12%, respectively. For HIT-6, 50% of patients had > 5 point reduction in score by cycle 7. No serious adverse events were reported. Conclusions: Results suggest durability of benefit for onabotulinumtoxinA based on the reduction in HA days after 7 treatments and in this small series of patients, through 9 treatments. OnabotulinumtoxinA demonstrated long-term improvements in migraine related disability as evaluated by the MIDAS and HIT-6 instruments. Results warrant investigation in a larger study to better understand the durability of onabotulinumtoxinA in clinical practice for chronic migraine. Study Supported by: Allergan Inc.

Disclosure: Dr. Blumenfeld has received personal compensation for activities with Pfizer Inc., Allergan Inc., Medtronic Inc., Merck & Co. Inc., Forest, and Keller Laboratories. Dr. Blumenfeld has received research support from Allergan Inc., Medtronic Inc., GlaxoSmithKline Inc., and Keller Laboratories. Dr. Inocelda has received personal compensation for activities with Allergan Inc. as an advisory board member. Dr. Cunanan has received personal compensation for activities with Allergan Inc. Dr. Purdy has received personal compensation for activities with Allergan Inc., Salix, and Astellas. Dr. Purdy has received research support from Allergan Inc., Salix, and Astellas. Dr. Dalfonso has received personal compensation for activities with Allergan Inc., Salix, and Astellas. Dr. Dalfonso has received research support from Allergan Inc., Salix, and Astellas. Dr. Magar has received personal compensation for activities with Allergan Inc., Salix, and Astellas. Dr. Magar has received research support from Allergan Inc., Salix, and Astellas.

Thursday, May 1 2014, 3:00 pm-6:30 pm

  • Copyright © 2014 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise